Status:
UNKNOWN
Rosuvastatin for Preventing Complications in Renal Ablation
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Arterial Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to test the hypothesis that twice overnight high-dose rosuvastatin loading before RNA followed by 3-month treatment with regular doses of rosuvastatin can reduce...
Detailed Description
Despite the availability and use of different classes of antihypertensive drugs, 5-30% of patients still show elevated blood pressure (EUROASPIRE III survey, 2011). Recently, a novel catheter-based r...
Eligibility Criteria
Inclusion
- Primary and idiopathic cause of resistant arterial hypertension defined as persistent systolic blood pressure persistent systolic blood pressure - 160 mm Hg, with at least established three antihypertensive medication (including diuretics)
- Patients with allergies to antihypertensive drugs
- Able to understand and willing to sign the informed CF
Exclusion
- Glomerular filtration rate \<45 mL/min
- LDL Cholesterol \>130 mg/dl
- Presence of coronary artery disease
- History of myopathy or elevated creatine kinase levels
- History of Impaired liver function and/or elevated ALT and/or AST levels
- Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before CT
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT01899027
Start Date
January 1 2014
End Date
December 1 2017
Last Update
July 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Sapienza
Rome, Italy, 00161